The use of Cancer/Testis antigens to monitor levels of circulating malignant stem cells in Multiple Myeloma.

Despite the development of sensitive methods to monitor the residual malignant plasma cell component in Multiple Myeloma (MM) patients, the current assays are limited in that they do not necessarily assess the complete malignant cellular component of the disease, cannot be applied to all MM patients and require painful BM assessments on a regular basis. There is therefore potential room for a completely different approach, investigating the monitoring of the proposed malignant stem cell feeder population circulating in the PB.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research